1. Home
  2. KNDI vs TCRX Comparison

KNDI vs TCRX Comparison

Compare KNDI & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KNDI

Kandi Technologies Group Inc

HOLD

Current Price

$0.76

Market Cap

67.8M

ML Signal

HOLD

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$0.98

Market Cap

75.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNDI
TCRX
Founded
2002
2018
Country
China
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.8M
75.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
KNDI
TCRX
Price
$0.76
$0.98
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
104.1K
580.7K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.28
EPS
N/A
N/A
Revenue
N/A
$10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$19.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
266.65
52 Week Low
$0.61
$0.88
52 Week High
$1.77
$2.57

Technical Indicators

Market Signals
Indicator
KNDI
TCRX
Relative Strength Index (RSI) 46.04 40.60
Support Level $0.68 $0.91
Resistance Level $0.79 $1.16
Average True Range (ATR) 0.05 0.06
MACD 0.01 -0.01
Stochastic Oscillator 47.90 21.57

Price Performance

Historical Comparison
KNDI
TCRX

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: